Sign in Subscribe
Genetic research

Advances and Challenges in Immunotherapy for Head and Neck Cancer

Strategic Insights

— 1 min read

Immunotherapy has transformed the treatment of head and neck squamous cell carcinoma (HNSCC), but despite advances, challenges persist in maximizing its potential. The current landscape of immunotherapy in HNSCC, including key clinical trials, emerging biomarkers, and novel therapeutic strategies, is being explored to overcome these challenges. Recent studies have shown potential benefits of perioperative immunotherapy in resectable disease and have established pembrolizumab as a standard of care for recurrent or metastatic HNSCC.

Key Takeaways:

  • Immunotherapy, particularly immune checkpoint inhibitors (ICIs), has transformed treatment paradigms for HNSCC, but its full potential is still being explored.
  • Phase III trials such as KEYNOTE-412 and JAVELIN Head and Neck 100 failed to demonstrate survival benefits with ICI-chemoradiotherapy combinations in unselected populations, but post hoc analyses suggest efficacy in PD-L1-positive tumors.
  • Recent studies, including KEYNOTE-689 and NIVOPOSTOP GORTEC 2018-01, indicate potential benefits of perioperative ICIs in resectable disease.
  • Biomarkers such as PD-L1 expression, tumor mutational burden (TMB), and Human Papillomavirus (HPV) status play a critical role in treatment selection, but further validation is needed.
  • Dual checkpoint blockade trials (KESTREL, CheckMate 651) have yielded mixed results, highlighting the complexity of immune resistance.
  • Emerging strategies include oncolytic virotherapy, chimeric antigen receptor-T cell therapy (CAR-T), and cancer vaccines, with promising preclinical and early-phase clinical results.
  • Challenges persist, including heterogeneous response rates, immune-related toxicities, and optimal integration of immunotherapy in multimodal treatment regimens.

Statistics:

  • PD-L1 expression is a key biomarker in treatment selection for HNSCC.
  • Recent studies have shown efficacy of perioperative ICIs in resectable disease in 20-30% of patients (KEYNOTE-689, NIVOPOSTOP GORTEC 2018-01).
  • KEYNOTE-040 and CheckMate 141 led to FDA approvals of pembrolizumab and nivolumab for recurrent or metastatic HNSCC.
  • 60% of patients with recurrent or metastatic HNSCC have a tumor CPS of 1 or greater (pembrolizumab monotherapy).

Sources:

  • (Frontiers in Immunology - http://journal.frontiersin.org/journal/immunology)
  • Study Results from Las Vegas in the Area of Cancer Gene Therapy Published (Advances and challenges in immunotherapy in head and neck cancer). Vaccine Weekly. June 25, 2025; p 63.

Read more